LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007655/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The general aim of this study is to investigate the efficacy and safety of afatinib (BIBW
2992) alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who
progress on afatinib monotherapy within this trial) as treatment in patients with
HER2-overexpressing, metastatic breast cancer, who failed HER2-targeted treatment in the
neoadjuvant or adjuvant setting
提供机构：
Vivli
创建时间：
2022-02-03
